# Novel Therapeutic Hypotheses for Age-Related Neurodegeneration ## 1. Senescence-Activated NAD+ Depletion Rescue **Description:** Senescent glial cells upregulate CD38 NADase, creating local NAD+ depletion zones that impair neuronal energy metabolism and synaptic function. Targeted CD38 inhibition or NAD+ precursor delivery to senescent cell neighborhoods could restore neuronal bioenergetics while preserving beneficial senescence functions. **Target:** CD38 NADase/NAMPT pathway **Supporting Evidence:** CD38 is highly expressed in senescent cells and correlates with NAD+ decline in aging brains (PMID: 32669541). NAD+ depletion precedes neuronal dysfunction in Alzheimer's models (PMID: 30674985). **Confidence:** 0.75 ## 2. SASP-Mediated Complement Cascade Amplification **Description:** Senescent astrocytes secrete C1q and other complement initiators, creating localized complement activation that tags healthy synapses for microglial elimination. Selective C1q or C3 inhibition in senescent cell microenvironments could prevent pathological synapse loss while maintaining immune surveillance. **Target:** C1Q/C3 complement proteins **Supporting Evidence:** SASP includes complement factors (PMID: 28065329), and complement-mediated synapse elimination drives cognitive decline (PMID: 26814963). C1q knockout protects against age-related synapse loss (PMID: 23328393). **Confidence:** 0.82 ## 3. Senescence-Induced Lipid Peroxidation Spreading **Description:** p16+ senescent cells exhibit dysregulated iron homeostasis and reduced antioxidant capacity, generating lipid peroxidation products (4-HNE, MDA) that propagate oxidative damage to neighboring neurons through gap junctions and extracellular vesicles. Targeted delivery of lipophilic antioxidants or iron chelators to senescent cells could break this propagation chain. **Target:** Ferroptosis pathway (GPX4, SLC7A11) **Supporting Evidence:** Senescent cells show increased iron accumulation and lipid peroxidation ... [truncated]

# Critical Evaluation of Age-Related Neurodegeneration Hypotheses ## 1. Senescence-Activated NAD+ Depletion Rescue ### Specific Weaknesses: - **Spatial specificity unclear**: No evidence that CD38 upregulation in senescent cells creates discrete "depletion zones" rather than global NAD+ reduction - **Causality assumption**: Correlation between CD38 expression and NAD+ decline doesn't establish that senescent cell CD38 is the primary driver - **Selective targeting challenge**: Mechanism for delivering NAD+ precursors specifically to "senescent cell neighborhoods" is undefined and likely technically unfeasible - **Functional senescence preservation**: No evidence that beneficial senescence functions exist or would be preserved by this approach ### Counter-evidence: - CD38 is also highly expressed in activated immune cells and other non-senescent cell types during neuroinflammation - NAD+ depletion occurs through multiple pathways including PARP activation during DNA damage, not just CD38 - Systemic NAD+ precursor supplementation shows mixed results in neurodegeneration trials ### Falsifying Experiments: 1. CD38 knockout in senescent cells specifically (using senescence markers) - if NAD+ levels don't improve locally, hypothesis fails 2. Spatial NAD+ mapping around individual senescent vs. non-senescent cells in brain tissue 3. Test whether CD38 inhibition prevents neurodegeneration in senescence-independent models ### Revised Confidence: 0.45 (reduced from 0.75) --- ## 2. SASP-Mediated Complement Cascade Amplification ### Specific Weaknesses: - **Normal vs. pathological distinction**: Complement-mediated synapse pruning is essential for normal brain development and plasticity - unclear how to distinguish beneficial from harmful elimination - **Localization assumption**: No evidence that senescent astrocytes create spatially restricted complement activation zones - **Timing issues**: C1q knockout studies show protection, but this m... [truncated]

# Druggability Assessment of Age-Related Neurodegeneration Hypotheses ## 1. Senescence-Activated NAD+ Depletion Rescue **Revised Confidence: 0.45** ### Druggability: HIGH **CD38 Inhibitors:** - **78c**: Potent, selective CD38 inhibitor (IC50 = 40 nM), brain-penetrant - **Kuromanin**: Natural flavonoid CD38 inhibitor, oral bioavailability - **Apigenin**: Dual CD38/CD157 inhibitor, clinical safety data available **NAD+ Precursors:** - **Nicotinamide riboside (NR)**: ChromaDex's NIAGEN®, FDA GRAS status - **Nicotinamide mononucleotide (NMN)**: Multiple suppliers, ongoing trials - **NAD+**: Direct IV administration (NAD+ injectable solutions) ### Existing Clinical Programs: - **NCT04482452**: NR in Alzheimer's disease (Washington University) - **NCT03816020**: NMN in healthy aging (University of Washington) - ChromaDex (NASDAQ: CDXC) - TRU NIAGEN® commercialized ### Competitive Landscape: - **Elysium Health**: BASIS (NR + pterostilbene) - $50M+ raised - **Alive by Science**: NMN products, direct-to-consumer - **Metro International Biotech**: NAD+ IV clinics expanding ### Safety Concerns: - CD38 inhibition may impair immune function (CD38 on NK cells, T cells) - High-dose NAD+ precursors linked to liver toxicity in some reports - Potential interference with normal circadian NAD+ cycling ### Timeline & Cost: - **Repurposing existing CD38 inhibitors**: 2-3 years, $20-50M - **Novel brain-penetrant CD38 inhibitor**: 5-7 years, $100-200M - **NAD+ precursor trials**: 1-2 years, $5-15M --- ## 2. SASP-Mediated Complement Cascade Amplification **Revised Confidence: 0.65** ### Druggability: MODERATE **C1q Inhibitors:** - **ANX005** (Annexon): Humanized anti-C1q mAb, brain-penetrant - **ANX007**: Next-gen C1q inhibitor with enhanced CNS penetration - **Mini-complement inhibitors**: Small molecule C1q antagonists in development **C3 Inhibitors:** - **Pegcetacoplan** (Apellis): Approved C3 inhibitor for PNH/GA - **APL-2**: Subcutaneous C3 inhibitor - **Com... [truncated]

```json { "ranked_hypotheses": [ { "title": "SASP-Mediated Complement Cascade Amplification", "description": "Senescent astrocytes secrete C1q and other complement initiators, creating localized complement activation that tags healthy synapses for microglial elimination. Selective C1q or C3 inhibition in senescent cell microenvironments could prevent pathological synapse loss while maintaining immune surveillance.", "target_gene": "C1Q/C3", "dimension_scores": { "mechanistic_plausibility": 0.75, "evidence_strength": 0.70, "novelty": 0.85, "feasibility": 0.75, "therapeutic_potential": 0.80, "druggability": 0.85, "safety_profile": 0.60, "competitive_landscape": 0.80, "data_availability": 0.75, "reproducibility": 0.70 }, "composite_score": 0.755 }, { "title": "Senescence-Activated NAD+ Depletion Rescue", "description": "Senescent glial cells upregulate CD38 NADase, creating local NAD+ depletion zones that impair neuronal energy metabolism and synaptic function. Targeted CD38 inhibition or NAD+ precursor delivery to senescent cell neighborhoods could restore neuronal bioenergetics while preserving beneficial senescence functions.", "target_gene": "CD38/NAMPT", "dimension_scores": { "mechanistic_plausibility": 0.65, "evidence_strength": 0.60, "novelty": 0.75, "feasibility": 0.70, "therapeutic_potential": 0.75, "druggability": 0.90, "safety_profile": 0.65, "competitive_landscape": 0.70, "data_availability":... [truncated]